The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered. | The days of broad stomach cancer labels ...
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...
"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric ...
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I 30, 2024 I Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology ...
Patients with NSCLC did not see a disease-free survival benefit with Imfinzi after surgery compared with taking a placebo.
The results showed that in patients with known CLDN18.2 and PD-L1 status, the median progression-free survival (mPFS) reached ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback